Page 22 - Naplex Q&A 2025 Version

www.pharmacyexam.com

82. Treatment with Clozaril should not be a. I only
initiated if the patient’s ANC count is less than: b. III only
c. I and II only
a. 1500/µL d. II and III only
b. 2500/ µL e. All
c. 3000/ µL
d. 3500/ µL 87. Rheumatrex is available in a:
e. 5,000/ µL
I. 5 mg/week dose pack
83. A patient should avoid sunlight while taking: II. 7.5 mg/week dose pack
III 10 mg/week dose pack
I. HydroDiuril
II. Mellaril a. I only
III. Sumycin b. III only
c. I and II only
a. I only d. II and III only
b. III only e. All
c. I and II only
d. II and III only 88. Nexium is available as a(n):
e. All
I. Delayed release capsule
84. Methotrexate is a(n): II. Delayed release oral suspension
III Injection for intravenous use
a. Folic acid antagonist
b. Prostaglandin antagonist a. I only
c. Alpha-1 blocker b. III only
d. Cyclooxygenase enzyme inhibitor c. I and II only
e. Thromboxane antagonist d. II and III only
e. All
85. Which of the following is/are folic acid
antagonists? 89. An overdose of Methotrexate can be
treated by:
I. Pyrimethamine
II. Triamterene a. Acetylcysteine
III Trimethoprim b. Sodium Polystyrene Sulfonate
c. Etidronate sodium
a. I only d. Leucovorin calcium
b. III only e. Mesna
c. I and II only
d. II and III only 90. During Methotrexate therapy, a patient
e. All should be monitored for:

86. Methotrexate should be avoided in this I. Creatinine clearance
patient because of his: II. SGPT level
III. WBC counts
I. High uric acid blood level
II. Renal failure a. I only
III. Hepatic failure b. III only

21